abstract |
Fully human anti-PD-L1 antibodies and their corresponding applications are disclosed. Fully human antibodies can specifically bind to human PD-L1. Antibodies were obtained by employing a yeast display library-based screening technique and by affinity maturation which further improves the affinity for PD-L1. The fully human anti-PD-L1 antibodies disclosed show good specificity, affinity, stability. They can enhance T cell activity by binding to activated T cells while significantly inhibiting tumor growth. The disclosed fully human anti-PD-L1 antibodies can be used in the diagnosis and treatment of PD-L1-related cancers and other related diseases. |